Keyphrases
Epstein-Barr Virus
100%
Virus-specific
100%
Adoptive Immunotherapy
100%
Recurrent Metastatic
100%
Recurrent Nasopharyngeal Carcinoma
100%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
44%
Chemotherapy
22%
Disease Progression
22%
Patient Demographics
11%
Informed Consent
11%
Clinical Response
11%
Metastatic Disease
11%
Overall Response Rate
11%
Accruals
11%
Remission
11%
Median Overall Survival
11%
Median Progression-free Survival
11%
Specific Immunotherapy
11%
Viral Load
11%
Chemotherapy Regimen
11%
Cytotoxic T Lymphocytes
11%
Good Prognosis
11%
Tumor-associated
11%
Viral Antigens
11%
Complete Response
11%
Durable Response
11%
Product Manufacturing
11%
Phase 1/2 Study
11%
Standard-of-care Chemotherapies
11%
Lymphocyte Immunotherapy
11%
Medicine and Dentistry
Epstein Barr Virus
100%
Nasopharynx Carcinoma
100%
Adoptive Immunotherapy
100%
Immunotherapy
55%
Nasopharynx Cancer
44%
Chemotherapy
33%
Disease Exacerbation
22%
Neoplasm
11%
Overall Survival
11%
Progression Free Survival
11%
Metastatic Carcinoma
11%
Patient Population
11%
Chemotherapy Regimens
11%
Malignant Neoplasm
11%
Informed Consent
11%
Virus Antigen
11%
Cytotoxic T-Cell
11%
Pharmacology, Toxicology and Pharmaceutical Science
Epstein-Barr Virus
100%
Nasopharynx Carcinoma
100%
Immunotherapy
100%
Nasopharynx Cancer
44%
Chemotherapy
33%
Disease Exacerbation
22%
Malignant Neoplasm
11%
Metastasis
11%
Overall Survival
11%
Progression Free Survival
11%
Remission
11%
Virus Antigen
11%
Chemotherapy Regimens
11%
Neoplasm
11%